ASH 2017 | CLARITY: a Phase 2 trial using venetoclax and ibrutinib

Francesco Forconi

CLARITY is a Phase II clinical trial studying the combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL). In this video, Francesco Forconi, MD, DM, PhD, FRCPath from the University of Southampton, Southampton, UK discusses the results presented at the American Socienty of Hematology (ASH) 2017 Annual Meeting, held in Atlanta, GA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter